Thought I would add a few more substantive comments vis-a-vis FOLD... FOLD focuses on orphan drugs, which means small markets. It's leading drug in the pipeline is AT1001, which is designed to treat a rare genetic disorder of Fabry diesase. How rare is Fabry Disease? 1 in 40-50,000 people are inflicted in USA or about 3,800 -6,000, based on statistics. Not a huge market, consequently not a huge money maker.
Present treatment of this genetic disorder is through a combination of enzymes. FAbrazyme is already approved in US but has some shortcomings. Another enzyme replacement drug is Replagal, approved in Europe, but not in US - yet. It is with this backdrop of already approved drugs that FOLD is competing. Commercialization of an orphan drug, in light of two other drugs on the market which apparently work for a very small market. Hmmm.
FOLD has two other drug candidates to treat Pompe and Gaucher disease, all of them in pre-clinical testing. Simply stated, these drug candidates are not even close to beginning FDA phases 1, 2 or 3 of commercial development and approval.
According to FOLD's own website, preclinical testing to drug approval involves many critical steps and up to ten years for approval. Critical steps means that such drug testing is extraordinarily expensive and subject to setbacks and further testing mandates.
It is noted, that before dilution, company is losing $1.28 per share.
Yes, I am short and will expect to stay that way for at least the intermediate term.